Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 4/2013

THE EFFICIENCY OF METOPROLOL TARTRATE IN THE TREATMENT OF PURE ARTERIAL HYPERTENSION AT PATIENTS WITH CORONARY ARTERY DISEASE AND THE RISK FACTORS ASSOCIATED

DANIEL LAURENTIU COZLEA1, DAN MIRCEA FĂRCAŞ1*, CAMIL VARI2, ARTHUR-ATILLA KERESZTESI3, RAMONA ŢIFREA1, LAURENTIU COZLEA1, GRIGORE DOGARU4

1Clinica Medicala III, University of Medicine and Pharmacy of Târgu-Mureş, Romania
2Discipline of Pharmacology, University of Medicine and Pharmacy of Târgu-Mureş, Romania
3Institute of Legal Medicine, Târgu Mureş University of Medicine and Pharmacy, Romania
4Department of Nephrology, University of Medicine and Pharmacy of Târgu-Mureş, Romania

Download Full Article PDF

The aim of the present study was to evaluate the efficiency of metoprolol tartrate of various concentrations in the treatment of patients with diverse forms of hypertension - pure, with comorbidities and/or complications (coronary artery disease, heart failure), in the absence of contraindications for the use of betablockers. The study was performed at the Medical Clinic Nr. 3 - Cardiology of Târgu Mureș, between June 1st 2009 - September 1st 2010, involving a group of 200 patients, 128 men and 72 women, with an average age of 51.7 ± 7.2 years (32-77 years), diagnosed with hypertension (HT), without prior antihypertensive medication - 116 patients, or with a history of hypertension (1-15 years at the moment of diagnosis) and various ambulatory therapeutic schemes of questionable efficiency - 84 patients, in which the ambulatory treatment could not lower blood pressure values below 150/90 mmHg. Based on our results we consider that the administration of metoprolol tartrate in various concentrations is indicated in all hypertensive patients, in the absence of contraindications for the use of betablockers. Our study concluded that monotherapy is efficient mainly in young patients and patients with recently diagnosed HT with or without treatment, provided the treatment is maximum 4-5 years old, and the patient has not been given betablockers before. Older patients, with comorbidities or HT related complications need an association of drugs in 80% of cases, excluding the medication used in the treatment of comorbidities or complications. As far as the cost-efficiency ratio is concerned, the examined drug deserves a maximum number of points in both regards,